




RealRate

# PHARMACEUTICAL 2022

Celularity Inc  
Rank 371 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Celularity Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celularity Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Celularity Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 184% points.

The company's Economic Capital Ratio, given in the ranking table, is 172%, being 103% points below the market average of 275%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 59,100            |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 246,491           |
| Liabilities, Current                        | 26,225            |
| Liabilities, Non-Current                    | 2,206             |
| Other Assets                                | 17,912            |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | -29,280           |
| Other Liabilities                           | 286,279           |
| Other Net Income                            | 8,961             |
| Other Revenues                              | 21,335            |
| Property and Equipment                      | 90,625            |
| Research and Development                    | 88,353            |
| Selling, General and Administrative Expense | 71,341            |

| Output Variable             | Value in 1000 USD |
|-----------------------------|-------------------|
| Assets                      | 414,128           |
| Liabilities                 | 314,710           |
| Expenses                    | 130,414           |
| Revenues                    | 21,335            |
| Stockholders Equity         | 99,418            |
| Net Income                  | -100,118          |
| Comprehensive Net Income    | -100,118          |
| BaseVar                     | 444,774           |
| ECR before LimitedLiability | 32%               |
| Economic Capital Ratio      | 172%              |